Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

Back to Search
Print
Bookmark Trial

NCT01072396

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
205.440.1006 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, , United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Obstructive Pulmonary Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

For COPD subjects: Male or female, age of 40 years or older, smoking history >10 pack-years, symptomatic defined as baseline dyspnea index focal score of 9 or more and / or daily cough with production of sputum for three months per year during at least two consecutive years, diagnosis of early stage COPD according to: post-bronchodilator FEV1/FVC ratio <70%., FEV1 >/=50% post-bronchodilator predicted normal, and a decreased Inspiratory Capacity during exercise. For Age / Gender Matched Controls: Male or female, age of 40 years or older, nonsmoker, with no significant diseases.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Patients with a significant disease other than COPD; a significant disease is defined as a
disease which, in the opinion of the investigator, may (i) put the patient at risk because
of participation in the study, (ii) influence the results of the study, or (iii) cause
concern regarding the patient's ability to participate in the study.


Patients with a history of asthma, Patients requiring the use of supplemental oxygen
therapy, Patients who have a limitation of exercise performance as a result of factors
other than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris,
claudication or other conditions, or Patients with contraindications to exercise.


Note: Additional exclusion criteria for Age / Gender Matched Controls: Patients with a
significant disease including COPD.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Chronic Obstructive Pulmonary DiseaseEffects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
NCT01072396
  1. Birmingham, Alabama
  2. Jasper, Alabama
  3. Torrance, California
  4. Hartford, Connecticut
  5. Springfield, Illinois
  6. Muncie, Indiana
  7. Livonia, Michigan
  8. Lebanon, New Hampshire
  9. Charlotte, North Carolina
  10. Pittsburgh, Pennsylvania
  11. Spartanburg, South Carolina
  12. Kingston, Ontario
  13. Montreal, Quebec
  14. Montreal, Quebec
  15. Ste-Foy, Quebec
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseaseCOPE With COPD Trial
NCT02343055
  1. Amherstburg, Ontario
  2. Chatham, Ontario
  3. Harrow, Ontario
  4. Leamington, Ontario
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseaseAssessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test
NCT01644734
  1. Andrychow,
  2. Bialystok,
  3. Bialystok,
  4. Bialystok,
  5. Bialystok,
  6. Bialystok,
  7. Bielsko-Biala,
  8. Bielsko-Biala,
  9. Bielsko-Biala,
  10. Biskupiec,
  11. Bochnia,
  12. Brzesko,
  13. Brzesko,
  14. Brzeziny,
  15. Brzozow,
  16. Bydgoszcz,
  17. Bydgoszcz,
  18. Bydgoszcz,
  19. Bydgoszcz,
  20. Bydgoszcz,
  21. Chelmsko Slaskie,
  22. Chelm,
  23. Chelm,
  24. Chodziez,
  25. Chojnice,
  26. Chorzow,
  27. Chorzow,
  28. Ciechanow,
  29. Czarnkow,
  30. Czestochowa,
  31. Czestochowa,
  32. Dabrowa Gornicza,
  33. Domaradz,
  34. Dziergowice,
  35. Gdansk,
  36. Gdansk,
  37. Gdansk,
  38. Gdansk,
  39. Gdansk,
  40. Gdansk,
  41. Gdansk,
  42. Gdansk,
  43. Gdynia,
  44. Gliwice,
  45. Glucholazy,
  46. Gora,
  47. Gorzow Wielkopolski,
  48. Grodzisk Mazowiecki,
  49. Grodzisk Mazowiecki,
  50. Gryfice,
  51. Jaroslaw,
  52. Jaslo,
  53. Jaslo,
  54. Jaslo,
  55. Jedrzejow,
  56. Jelenia Gora,
  57. Katowice,
  58. Katowice,
  59. Katowice,
  60. Katowice,
  61. Kcynia,
  62. Kielce,
  63. Kielce,
  64. Kielce,
  65. Klodzko,
  66. Kolobrzeg,
  67. Konin,
  68. Konskie,
  69. Konskie,
  70. Koszalin,
  71. Koszalin,
  72. Krakow,
  73. Krakow,
  74. Krakow,
  75. Krakow,
  76. Krakow,
  77. Krakow,
  78. Krakow,
  79. Krakow,
  80. Krakow,
  81. Krasnik,
  82. Krasnik,
  83. Krasnik,
  84. Krosno,
  85. Kutno,
  86. Ledziny,
  87. Legionowo,
  88. Lisnik Duzy,
  89. Lodz,
  90. Lodz,
  91. Lodz,
  92. Lodz,
  93. Lodz,
  94. Lomza,
  95. Lomza,
  96. Lowicz,
  97. Luban,
  98. Lubartow,
  99. Lubin,
  100. Lubin,
  101. Lubin,
  102. Lubliniec,
  103. Lublin,
  104. Lublin,
  105. Lublin,
  106. Lublin,
  107. Lubon,
  108. Ludwikowo,
  109. Lukow,
  110. Makow Mazowiecki,
  111. Malbork,
  112. Mielec,
  113. Milicz,
  114. Myslowice,
  115. Myszkow,
  116. Nisko,
  117. Nowy Dwor Gdanski,
  118. Nowy Sacz,
  119. Olawa,
  120. Olecko,
  121. Olsztyn,
  122. Opatow,
  123. Ostrowiec Swietokrzyski,
  124. Ostrowiec Swietokrzyski,
  125. Pabianice,
  126. Papowo Biskupie,
  127. Pawonkow,
  128. Piekary Slaskie,
  129. Pietrzykowice,
  130. Pila,
  131. Piotrkow Trybunalski,
  132. Plock,
  133. Pniewy,
  134. Poniatowa,
  135. Poznan,
  136. Poznan,
  137. Poznan,
  138. Poznan,
  139. Poznan,
  140. Prabuty,
  141. Proszowice,
  142. Pruszcz Gdanski,
  143. Przemysl,
  144. Rabka Zdroj,
  145. Radom,
  146. Radom,
  147. Ruda Slaska,
  148. Ruda Slaska,
  149. Ruda Slaska,
  150. Ruda Slaska,
  151. Rumia,
  152. Rumia,
  153. Rumia,
  154. Rybnik,
  155. Rybnik,
  156. Rybnik,
  157. Rzeszow,
  158. Rzeszow,
  159. Sanok,
  160. Sawin,
  161. Sejny,
  162. Siewierz,
  163. Skarzysko Kamienna,
  164. Skawina,
  165. Skoczow,
  166. Skrzyszow,
  167. Slawno,
  168. Slubice,
  169. Slupca,
  170. Sokolowsko,
  171. Sopot,
  172. Sosnowiec,
  173. Sosnowiec,
  174. Srem,
  175. Srem,
  176. Stalowa Wola,
  177. Starachowice,
  178. Starachowice,
  179. Stargard Szczecinski,
  180. Sucha Beskidzka,
  181. Suprasl,
  182. Suwalki,
  183. Suwalki,
  184. Swidnik,
  185. Swiecie,
  186. Sycow,
  187. Szczecinek,
  188. Szczecin,
  189. Szczecin,
  190. Szczecin,
  191. Szczecin,
  192. Szczecin,
  193. Tarnobrzeg,
  194. Tarnobrzeg,
  195. Tarnowskie Gory,
  196. Tarnow,
  197. Tarnow,
  198. Torun,
  199. Torun,
  200. Torun,
  201. Trzcianka Lubuska,
  202. Twardogora,
  203. Tychy,
  204. Tychy,
  205. Uchanie,
  206. Walcz,
  207. Warszawa,
  208. Warszawa,
  209. Warszawa,
  210. Warszawa,
  211. Warszawa,
  212. Warszawa,
  213. Warszawa,
  214. Warszawa,
  215. Warszawa,
  216. Warszawa,
  217. Warszawa,
  218. Warszawa,
  219. Warszawa,
  220. Warszawa,
  221. Warszawa,
  222. Wejherowo,
  223. Wieliczna,
  224. Wielun,
  225. Witonia,
  226. Wloc³awek,
  227. Wodzislaw Slaski,
  228. Wolomin,
  229. Wroclaw,
  230. Wroclaw,
  231. Wroclaw,
  232. Wroclaw,
  233. Wroclaw,
  234. Wroclaw,
  235. Wroclaw,
  236. Zabkowice Slaskie,
  237. Zabkowice Slaskie,
  238. Zabrze,
  239. Zabrze,
  240. Zabrze,
  241. Zagoty,
  242. Zblewo,
  243. Zgierz,
  244. Zielona Gora,
  245. Zielona Gora,
  246. Zielonka k/Warszawy,
  247. Zyrardow,
ALL GENDERS
0+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseaseTrial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
NCT00523991
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Jasper, Alabama
  4. Palo Alto, California
  5. San Diego, California
  6. Lexington, Kentucky
  7. Baltimore, Maryland
  8. Bloomington, Minnesota
  9. Rochester, Minnesota
  10. Omaha, Nebraska
  11. Albuquerque, New Mexico
  12. Rochester, New York
  13. Charlotte, North Carolina
  14. Cincinnati, Ohio
  15. Pittsburgh, Pennsylvania
  16. Kingsport, Tennessee
  17. Clarksburg, West Virginia
  18. Gilly,
  19. Leuven,
  20. Menen,
  21. Yvoir,
  22. Vancouver, British Columbia
  23. Kingston, Ontario
  24. Toronto, Ontario
  25. Ste-Foy, Quebec
  26. Cvikov,
  27. Hradec Kralove,
  28. Karlovy Vary,
  29. Liberec,
  30. Neratovice,
  31. Pardubice,
  32. Praha 10,
  33. Praha 3,
  34. Praha 6,
  35. Strakonice,
  36. Tabor,
  37. Usti nad Labem,
  38. Berlin,
  39. Berlin,
  40. Gelnhausen,
  41. Rüdersdorf,
  42. Ulm,
  43. Athens,
  44. Athens,
  45. Thessaloniki,
  46. Enschede,
  47. Etten Leur,
  48. Spijkenisse,
  49. Zutphen,
  50. Amadora,
  51. Coimbra,
  52. Lisboa,
  53. Dnipropetrovsk,
  54. Kharkiv,
  55. Kharkov,
  56. Kharkov,
  57. Kiev,
  58. Kiev,
  59. Simferopol,
  60. Garston, Watford,
  61. Harrow,
  62. Warminster,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
Official Title  ICMJE A Randomized, Double-blind, Placebo-controlled, 6-week, Crossover Study to Examine the Effects of Tiotropium (Spiriva® HandiHaler®, 18 µg Once Daily) on Dynamic Hyperinflation and Physical Exercise Capacity in Patients With Early Stage Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary Optimal clinical management in early stages of COPD is not established. Tiotropium has been shown to improve exercise tolerance during (CWR) cycle ergometry with GOLD stage II to IV COPD, improvements in constant speed treadmill time in a study of patients who also received pulmonary rehabilitation in a population of patients with predominantly severe and very severe disease (GOLD stages III and IV) and improvements in exertional dyspnea, and Shuttle Walk Test distance in GOLD stage III and IV COPD. However, data are lacking on the benefits of tiotropium on exercise tolerance in a patients with early stages of COPD who are symptomatic. Patients with milder ventilatory limitations (GOLD stages I/II COPD patients) may benefit from maintenance therapy and there is limited data on exercise limitation in patients with early stage COPD who are symptomatic. This study is designed to evaluate the mechanisms of breathlessness and assess physical activity limitation in early stage COPD patients compared to age and gender matched controls and will secondly investigate the effectiveness of treatment with tiotropium in improving dyspnea during exercise and exercise duration as a result of the bronchodilation effects of tiotropium leading to a reduction of dynamic hyperinflation in Early Stage COPD patients.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Pulmonary Disease, Chronic Obstructive
Intervention  ICMJE
  • Drug: Tiotropium
    double blind randomized crossover
  • Drug: Placebo
    inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
Study Arms  ICMJE
  • Active Comparator: 18 mcg tiotropium
    Patient to receive 1 tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
    Intervention: Drug: Tiotropium
  • Placebo Comparator: Placebo
    Patient to receive 1 placebo inhalation powder capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
    Intervention: Drug: Placebo
  • No Intervention: Control
    Age and gender matched control subjects to conduct incremental and constant work rate exercise tests for comparison to subjects with early stage COPD
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 27, 2011)		126
Original Estimated Enrollment  ICMJE
 (submitted: February 19, 2010)		124
Actual Study Completion Date  ICMJE November 2011
Actual Primary Completion Date November 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

For COPD subjects: Male or female, age of 40 years or older, smoking history >10 pack-years, symptomatic defined as baseline dyspnea index focal score of 9 or more and / or daily cough with production of sputum for three months per year during at least two consecutive years, diagnosis of early stage COPD according to: post-bronchodilator FEV1/FVC ratio <70%., FEV1 >/=50% post-bronchodilator predicted normal, and a decreased Inspiratory Capacity during exercise. For Age / Gender Matched Controls: Male or female, age of 40 years or older, nonsmoker, with no significant diseases.

Exclusion criteria:

Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study.

Patients with a history of asthma, Patients requiring the use of supplemental oxygen therapy, Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris, claudication or other conditions, or Patients with contraindications to exercise.

Note: Additional exclusion criteria for Age / Gender Matched Controls: Patients with a significant disease including COPD.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 40 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01072396
Other Study ID Numbers  ICMJE 205.440
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boehringer Ingelheim
Study Sponsor  ICMJE Boehringer Ingelheim
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair:Boehringer IngelheimBoehringer Ingelheim
PRS Account Boehringer Ingelheim
Verification Date April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP